Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results

Madrigal Pharmaceuticals reported third-quarter 2026 Rezdiffra net sales of $431.3 million, up 50% year over year, with year-to-date sales exceeding $1.1 billion. The company posted its first profitable quarter, earning $55.4 million, or $1.83 per diluted share, compared with a $114.2 million net loss a year earlier. Madrigal also plans to launch MAESTRO-CSPH, a Phase 3 outcomes trial for F4c patients with clinically significant portal hypertension, alongside its ongoing MAESTRO-NASH OUTCOMES study.